Molecular Biology Enzymes, Kits, and Reagents Market Size and Share - Global Growth, Regional Outlook, Revenue Estimation and Forecasts, 2024-2030

Market Overview

The size of the molecular biology kits & reagents and enzymes market was USD 18.4 Billion in 2023, and it will power at a rate of 18.0 % from 2024 to 2030, reaching USD 57.8 Billion by 2030.

The major factors propelling the growth of the market are the increase in genomic research, high government and private funding for healthcare R&D, and surging burden of genetic diseases. The steadily advancing technologies of molecular biology have a substantial influence on the life science research being done for the improvement of healthcare. These studies drive the use of consumables, including molecular biology enzymes, reagents, and kits. Further, the adoption of bioinformatics and computational tools for genome examination and drug discoveries is a major trend in the market.

Market Dynamics

The pandemic had a positive impact on the development of the industry, by leading to the introduction of numerous novel test kits and diagnostic products.

• For instance, in January 2020, Bio-Rad Laboratories introduced its novel SEQuoia Complete Stranded RNA library prep kit intended for the initial step of library preparation throughout RNA sequencing. This novel kit displays high compatibility with various samples, including degraded RNA samples throughout transit.

Furthermore, the introduction of new molecular diagnostic instruments by the players of the industry propelled the use of the consumables. Moreover, scientists strove for creating massive biological databases of patients infected with the SARS-CoV2 virus and used computational approaches together with sequencing methods, which, thus, led to a surge in the use of molecular biology enzymes, reagents, and kits.

Moreover, the biggest driver for the market is the growing number of genome projects. Since genetic mutations govern the formation of cancer and the risk of several other neurological, orthopedic, and cardiac conditions, metagenomic sequencing is being carried out on a large scale to understand how these diseases develop. By storing the information generated in secure databases for analysis, scientists hope to create more-effective and safer treatments.

• The most-prominent of these, the Human Genome Project, has sequenced over 3 billion chemical base pairs of the DNA.

Another key aspect driving genetic research is synthetic biology, which aims to generally engineer organisms to serve purposes in medicine, agriculture, and industries. Vaccine & antibody production, biofuels, GM crops, biologically sourced agrochemicals, and faster fermentation techniques that offer higher yields in food processing are all possible applications of synthetic biology. All these fields depend on an array of molecular biology kits, enzymes, and reagents, which is the key reason for the market growth.

Bioprocessing and industrial applications signify a substantial growth avenue for the industry. Enzymes have an important role to play in bioprocessing, providing sustainable solutions for numerous industrial applications. Their ability to catalyze precise reactions efficiently is harnessed in food & beverage processing, biofuel production, and pharma manufacturing. The shift toward green chemistry and practices furthers the prospects for eco-friendly enzyme usage in industrial procedures.

Enzymes contribute to the enhancement of production procedures, decreasing energy consumption and waste generation. Their adaptability in breaking down intricate substrates improves the efficiency of bioprocessing, making them valued among companies using bio-based substitutes. As industries prioritize ecologically conscious practices, the requirement for molecular biology enzymes in bioprocessing and industrial uses will grow.

Molecular Biology Enzymes, Kits, and Reagents Market Report Coverage

Report Attribute	Details
Market Size in 2023	USD 18.4 Billion
Revenue Forecast in 2030	USD 57.8 Billion
Growth Rate	18.0% CAGR
Historical Years	2017-2023
Forecast Years	2024-2030
Report Scope	Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling

Explore more about this report - Request free sample

 

Segmentation Analysis

The pharmaceutical & biotechnology companies category has a significant share under the end user segment. This is because of the extensive acceptance of PCR, sequencing, genotyping, and DNA/RNA extraction enzymes to make the workflow easier. The usage convenience and effectiveness of these products during research for drug candidates, tailored medicine, and diagnostics boost the adoption of the molecular biology approach among pharmaceutical & biotechnology corporations. Additionally, the high adoption of molecular technologies during clinical trials will power this category in the years to come.

The academic and research institutes category is also displaying considerable growth. The increase in the requirement for novel diagnostic tools and treatment options for COVID-19 increased the demand for many types of kits, assays, and reagents at research centers. In addition, the wide use of NGS and PCR fuels progress in research projects, the number of which continues to grow. A lot of the research is focused on CRISPR and precision medicine, thus driving the usage of the associated consumables.

In this regard, government research grants contribute to the development of the industry.

• In April 2021, the NIH gave a grant of USD 10.8 million to the University of Arkansas for the formation of the Arkansas Integrative Metabolic Research Center for biomedical research.

Kits and reagents have the larger share in the industry, because of the vast obtainability of these products, which was fueled by the increasing count of SARS-CoV-2 variants.

• PerkinElmer introduced NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 in December 2021 for disease surveillance and augmentation of sequencing throughput and dependability for variant identification. The firm further made this kit compatible with the Illumina platform.

Enzymes will witness the faster growth in sales owing to the adoption of the cloning technology in routine lab practice. This has encouraged players to offer numerous enzymes for nucleic acid manipulation. The existence of diverse sources of polymerases, ligases, nucleases methylases, phosphatases, and topoisomerases for cloning applications has enabled the progress of cloning techniques. Furthermore, companies are trying to develop novel and cutting-edge enzymes.

• In November 2021, Novozymes and Novo Nordisk cooperated to create specialty enzymes for biologic production.

The PCR category holds a remarkable share in the application segment. PCR equipment costs less and is used by the majority of the pharma & biotech companies, academic & research institutes, and hospitals & diagnostic laboratories. Moreover, RT-PCR was promoted by governments and private bodies as an effective test for COVID-19. Therefore, companies in the market launched several RT-PCR kits and kept advancing them as COVID-19 variants evolved. Additionally, the rising demand for highly replicable polymerases and hot-start PCR enzymes is propelling the market in this category.

The sequencing category is expected to showcase a healthy CAGR in the forecast period, driven by the rising usage of this approach for genomic studies, tumor profiling, and biomarker discovery. In this regard, NGS is a key trend, with this technology finding increasing usage in precision medicine, with the decreasing cost of such procedures.

Geographical Insights

North America is the leader of the industry, and it will continue to do so over this decade.

• The high occurrence of cancer in all age groups is driving the extent of research on diagnosis and treatment.
• The existence of well-known players and prominent research institutes, substantial private and government funding, advanced healthcare settings, and rapid acceptance of new technologies are the other major factors powering revenue generation in this region.

APAC will have a considerable growth rate in the years to come. The poor healthcare services, high populace, high rate of targetable illnesses, and quick economic development have created lucrative growth prospects for molecular biology kit, enzyme, and reagent producers. Moreover, the augmenting spending power in these nations has encouraged Western companies to introduce new products.

Major Companies Offering Molecular Biology Kits & Reagents and Enzymes:

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• Agilent Technologies Inc.
• QIAGEN N.V.
• Promega Corporation
• New England Biolabs
• Merck KGaA
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories Inc.
• Takara Bio Inc.
• LGC Limited
• Bausch Health Companies Inc.